196 related articles for article (PubMed ID: 25979393)
1. Systemic therapy for squamous cell carcinoma of the head and neck.
Pancari P; Mehra R
Surg Oncol Clin N Am; 2015 Jul; 24(3):437-54. PubMed ID: 25979393
[TBL] [Abstract][Full Text] [Related]
2. Molecular-targeted therapy of head and neck squamous cell carcinoma: beyond cetuximab-based therapy.
Machiels JP; Schmitz S
Curr Opin Oncol; 2011 May; 23(3):241-8. PubMed ID: 21358328
[TBL] [Abstract][Full Text] [Related]
3. Novel therapeutic approaches to squamous cell carcinoma of the head and neck using biologically targeted agents.
Harrington KJ; Kazi R; Bhide SA; Newbold K; Nutting CM
Indian J Cancer; 2010; 47(3):248-59. PubMed ID: 20587899
[TBL] [Abstract][Full Text] [Related]
4. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
Le Tourneau C; Siu LL
Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
[TBL] [Abstract][Full Text] [Related]
5. EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role?
Alorabi M; Shonka NA; Ganti AK
Crit Rev Oncol Hematol; 2016 Mar; 99():170-9. PubMed ID: 26797287
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab and cisplatin for chemotherapy-refractory squamous cell cancer of the head and neck.
Burtness B
J Clin Oncol; 2005 Aug; 23(24):5440-2. PubMed ID: 16009959
[No Abstract] [Full Text] [Related]
7. Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future directions.
Schmitz S; Ang KK; Vermorken J; Haddad R; Suarez C; Wolf GT; Hamoir M; Machiels JP
Cancer Treat Rev; 2014 Apr; 40(3):390-404. PubMed ID: 24176789
[TBL] [Abstract][Full Text] [Related]
8. Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck.
Bernier J
Nat Clin Pract Oncol; 2008 Dec; 5(12):705-13. PubMed ID: 18825142
[TBL] [Abstract][Full Text] [Related]
9. Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.
Iberri DJ; Colevas AD
Oncologist; 2015 Dec; 20(12):1393-403. PubMed ID: 26446236
[TBL] [Abstract][Full Text] [Related]
10. Current concepts for the management of head and neck cancer: chemotherapy.
Specenier PM; Vermorken JB
Oral Oncol; 2009; 45(4-5):409-15. PubMed ID: 18715812
[TBL] [Abstract][Full Text] [Related]
11. Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck.
Gilbert J; Argiris A
Clin Adv Hematol Oncol; 2006 Aug; 4(8):611-9. PubMed ID: 17099619
[TBL] [Abstract][Full Text] [Related]
12. The challenging integration of platinum compounds, taxanes, and molecular-targeted therapies in the multidisciplinary treatment of squamous cell carcinoma of the head and neck.
Awada A; Ismael G
Curr Opin Oncol; 2007 May; 19(3):177-9. PubMed ID: 17414633
[TBL] [Abstract][Full Text] [Related]
13. Integrating novel agents into the curative treatment of head and neck cancer.
Haddad R; Allen A; Wirth L; Tishler R; Posner M
Expert Rev Anticancer Ther; 2006 Feb; 6(2):157-9. PubMed ID: 16445367
[No Abstract] [Full Text] [Related]
14. Molecular-targeted therapies in head and neck cancer.
Rao SD; Fury MG; Pfister DG
Semin Radiat Oncol; 2012 Jul; 22(3):207-13. PubMed ID: 22687945
[TBL] [Abstract][Full Text] [Related]
15. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies.
Vermorken JB; Herbst RS; Leon X; Amellal N; Baselga J
Cancer; 2008 Jun; 112(12):2710-9. PubMed ID: 18481809
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor directed therapy in head and neck cancer.
Choong NW; Cohen EE
Crit Rev Oncol Hematol; 2006 Jan; 57(1):25-43. PubMed ID: 16207530
[TBL] [Abstract][Full Text] [Related]
17. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
Baselga J; Trigo JM; Bourhis J; Tortochaux J; Cortés-Funes H; Hitt R; Gascón P; Amellal N; Harstrick A; Eckardt A
J Clin Oncol; 2005 Aug; 23(24):5568-77. PubMed ID: 16009950
[TBL] [Abstract][Full Text] [Related]
18. Emerging drugs for head and neck cancer.
Rhee JC; Khuri FR; Shin DM
Expert Opin Emerg Drugs; 2004 May; 9(1):91-104. PubMed ID: 15155138
[TBL] [Abstract][Full Text] [Related]
19. Molecular targets in squamous cell carcinoma of the head and neck.
Shirai K; O'Brien PE
Curr Treat Options Oncol; 2007 Jun; 8(3):239-51. PubMed ID: 17962911
[TBL] [Abstract][Full Text] [Related]
20. The emerging role of cetuximab in head and neck cancer: a 2007 perspective.
Panikkar RP; Astsaturov I; Langer CJ
Cancer Invest; 2008 Feb; 26(1):96-103. PubMed ID: 18181051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
